Impact of Hydrocodone Rescheduling on Pharmaceutical Pain Management in End-of-Life Lung Cancer Patients
{{output}}
ObjectiveLung cancer is the leading cause of cancer mortality in the USA, and terminal patients endure severe pain. In October 2014, hydrocodone was rescheduled from Schedule III to Schedule II to curb misuse, yet its specific impact on end-of-life lung cancer... ...
